Search

Displaying results 2981 - 2990 of 10000 in total
  1. Drug

    Urethane

    go.drugbank.com/drugs/DB04827
    ApprovedWithdrawn

    Urethane, formerly marketed as an inactive ingredient in Profenil injection, was determined to be carcinogenic and was removed from the Canadian, US, and UK markets in 1963.

  2. Drug

    Purslane

    go.drugbank.com/drugs/DB14327
    Approved

    Purslane is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

  3. Drug

    Fendiline

    go.drugbank.com/drugs/DB08980
    ApprovedWithdrawn

    Fendiline is a coronary vasodilator which inhibits calcium function in muscle cells in excitation-contraction coupling. It has been proposed as an antiarrhythmic and antianginal agent.

    Products: SENSIT F
  4. Drug

    Selicrelumab

    go.drugbank.com/drugs/DB14958
    Investigational

    Selicrelumab is under investigation in clinical trial NCT01008527 (Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100).

  5. Drug

    Fluticasone

    go.drugbank.com/drugs/DB13867
    ApprovedInvestigationalWithdrawn

    Fluticasone is a synthetic glucocorticoid available as 2 esters, [DB08906] and [DB00588][F4355,F4358,F4361,F4364][FDA Label]. … These drugs are available as inhalers, nasal, sprays, and topical treatments for various inflammatory indications[F4355,F4358,F4361,F4364][FDA Label].

    Categories: Medications that reduce magnesium levels
  6. Drug

    D-fluoromethyltyrosine F-18

    go.drugbank.com/drugs/DB15296
    Investigational

    D-fluoromethyltyrosine F-18 is under investigation in clinical trial NCT01089998 (PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Safety and Tolerability in Healthy Volunteers and Safety … , Tolerability and Diagnostic Performance of BAY86-9596 in Patients With Non-small Cell Lung Cancer, Breast Cancer, Head and Neck Cancer and Patients With Inflammations).

  7. Drug

    Darusentan

    go.drugbank.com/drugs/DB04883
    Investigational

    Darusentan is a selective endothelin ETA receptor antagonist. It is being evaluated as a treatment for congestive heart failure and hypertension.

  8. Drug

    Remibrutinib

    go.drugbank.com/drugs/DB16852
    ApprovedInvestigational

    Remibrutinib is a selective Bruton's tyrosine kinase inhibitor. The FDA approved remibrutinib on September 30, 2025 as the only oral, targeted treatment for chronic spontaneous urticaria. … [L54101] Bruton's tyrosine kinase plays a role in B cell receptor and Fc receptor signalling, releasing histamine and pro-inflammatory mediators.

  9. Drug

    Edetic acid

    go.drugbank.com/drugs/DB00974
    ApprovedInvestigationalVet approved

    A chelating agent (chelating agents) that sequesters a variety of polyvalent cations. It is used in pharmaceutical manufacturing and as a food additive.

    Categories: Diet, Food, and Nutrition, Compounds used in a research, industrial, or household setting
  10. Drug

    Guselkumab

    go.drugbank.com/drugs/DB11834
    ApprovedInvestigational

    IL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade that induces psoriatic plaque formation [A20357]. … Guselkumab is a human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody that selectively blocks interleukin-23.

    Products: TREMFYA 100 MG/ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR KALEM, 2 ADET, TREMFYA 100 MG/ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR KALEM, 1 ADET